There is an unprecedented opportunity for healthcare to harness the power of new streams of patient monitoring and genetic data to tailor chronic disease management and cancer prevention for the unique patient in front of us. When we implemented Humanwide, a primary care project that used mobile monitoring devices regularly to track blood pressure, activity and weight, data was synthesized by the healthcare team to develop a care plan based on the patient’s goals with the principle of health equity in mind. Precision health can be more effective, more responsive, and treats the whole person.

There are currently more than 6,700 known single-locus disorders. Using phenotype-driven ultra-rapid whole genome sequencing (urWGS), it is possible to diagnose genetic disorders in as little as 13.5 hours, facilitating changes in clinical management from empiric therapy to disease-specific treatment and improving patient outcomes. urWGS diagnostic and clinical utility are well-established in neonatal and pediatric intensive care units, and next steps include scalability and widespread dissemination, areas in which automation (such as artificial intelligence and natural language processing) will play a significant role.

In 2018, Sanford Health began offering its primary care patients the Sanford Chip, a genetic test that provides pharmacogenomic profiling and optional screening for medically actionable predispositions. This talk summarizes data about the impact of the Sanford Chip program on healthcare providers and patients. Findings that will be discussed include the effectiveness of mandatory provider education efforts, the frequency of informative genetic findings, and early results about patient outcomes.

An increasing focus on wellness and prevention is key to dealing with chronic diseases that drive most health costs today.  Enabling predictive and preventive approaches requires the generation of dense data on healthy people to quantify wellness states and to observe the earliest transitions to disease. I will discuss how such 'deep phenotyping’ data is used to drive biological discovery and improve health.

Genomic medicine promises to help people understand and manage their health with individualized and actionable insights. An increasing number of health systems, biopharma companies, and others seek to build the programs needed to deliver on this promise, whether centered in research, clinical care or both. True end-to-end development, technology-enabled solutions, and scalable genetic services are required to deliver the right care to the right patient at the right time.

The interaction between the microbiome and the human host holds the key to the triggers and progression of many chronic diseases. By analyzing large host-microbiome gene expression datasets obtained from blood, stool, and saliva samples, we have discovered biomarkers and therapeutic targets for multiple chronic diseases and cancer, and translated them into clinical applications. We invite collaborators to leverage our platform to discover insights at this frontier of systems biology.

Fresh off a record year of venture dollars into health technology, investment interest in precision medicine and digital health is quickly picking up speed. But venture dollars and market adoption don't always see eye-to-eye. In this interactive discussion, Adam Dakin, Partner of Dreamit Venture's healthtech investment vertical, highlights the adoption barriers that precision medicine companies currently face and what the sector needs to overcome to meet the promise (and returns) that investors expect.

What’s driving innovation in healthcare? SVB provides unique insight into the ecosystem with its industry-leading reports featuring proprietary analysis and targeted outlooks informed by our deep relationships with top healthcare entrepreneurs and investors. Twice a year we publish deep-dive analysis of fundraising, investment and exit activity of private, venture-backed biopharma, healthtech, diagnostics/tools and device companies to help companies and investors achieve their goals.

For the adoption of technologies to become tangible and real, we need to continue to evaluate them with great scientific vigor. Join the conversation to take a deep dive into the promise of precision medicine and how it can be best used in practice.

Parthen offers precision oncology services to patients, their caregivers, and Primary Clinical Care Team.  Using a patient-centered globally connected digital health platform, Parthen offers guidance on molecular testing, patient advocacy/navigation services and medication acquisition specialists to best support cancer patients and their families. 

Recent technological advances as well as longitudinal monitoring not only have the potential to improve the treatment of disease (Precision Medicine) but also empower people to stay healthy (Precision Health). We have been using advanced multiomics technologies (genomics, immunomics, transcriptomics, proteomics, metabolomics, microbiomics) as well as wearables for monitoring health in 109 individuals for up to 11 years and made numerous major health discoveries covering cardiovascular disease, oncology, metabolic health and infectious disease. We have found that individuals have distinct aging patterns that can be measured in an actionable period of time as well as seasonal patterns of health markers. Finally, we have used wearable devices for early detection of infectious disease, including COVID-19 and built an alerting system for detecting health stressors that is scaleable to the entire planet. We believe that advanced technologies have the potential to transform healthcare.

Accelerating precision medicine at a Health System level is the holy grail for patients and healthcare professionals alike. Several technical, regulatory, and cultural hurdles currently complicate the largescale implementation of data-driven individualized healthcare decisions and precision medicine approaches. This talk will review a vision for “learning from a million patients to better care for the one” through scalable biobanking and research information solutions in the Cleveland Clinic Health System.

Diagnostic sequencing for rare disease using whole genome is becoming a routine part of care for critically ill newborns as well as children with undiagnosed diseases, enabled by Fabric Genomics GEM AI technology. This technology is now being leveraged for identifying disease-causing variants among ostensibly healthy individuals in the screening setting. Potential applications, including genome-wide newborn screening, carrier testing and adult hereditary risk profiling, will be discussed.

High fidelity, high-quality Real World Data can be obtained by placing the patient at the center, breaking down data silos to obtain comprehensive, longitudinal health data. Such data is critical for Precision Medicine as well as for clinical studies leading to the discovery of novel cures. Health Data is Medicine.

Dr. Foschini will give examples of applications of Person-Generated Health Data (PGHD) across therapeutic areas, including post-op monitoring, screening for cognitive impairment, and COVID-19 detection and quantification. Finally, Dr. Foschini will discuss lessons learned in translating PGHD research into benefit for the individuals, and how good analytic performance is a necessary but not at all sufficient condition to engender the trust that clinical investigators, doctors, regulators, and ultimately individuals seek.

In an era of smart devices and sensors, we now have the ability to finally understand our patient's physiology beyond the snapshots we get in the clinic. However, many clinical studies continues to rely on the bottleneck of referrals through clinic visits. In this talk we will discuss the major digital clinical studies, the promises and challenges of digital clinical trials and some future directions.